AMLX | Amylyx Pharmaceuticals, Inc.

Index	-	P/E	-	EPS (ttm)	-2.48	Insider Own	23.46%	Shs Outstand	66.72M	Perf Week	-4.26%
Market Cap	1.64B	Forward P/E	8.68	EPS next Y	2.90	Insider Trans	-6.72%	Shs Float	49.98M	Perf Month	-10.30%
Income	-149.00M	PEG	-	EPS next Q	0.04	Inst Own	65.70%	Short Float / Ratio	17.06% / 8.24	Perf Quarter	-26.42%
Sales	93.70M	P/S	17.53	EPS this Y	-117.80%	Inst Trans	34.24%	Short Interest	8.53M	Perf Half Y	-34.38%
Book/sh	5.29	P/B	4.76	EPS next Y	309.89%	ROA	-49.40%	Target Price	49.17	Perf Year	194.50%
Cash/sh	5.30	P/C	4.75	EPS next 5Y	-	ROE	-57.80%	52W Range	8.35 - 41.93	Perf YTD	-31.85%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-59.30%	52W High	-39.95%	Beta	-
Dividend %	-	Quick Ratio	7.30	Sales past 5Y	-	Gross Margin	91.20%	52W Low	201.56%	ATR	1.35
Employees	262	Current Ratio	7.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	38.36	Volatility	5.64% 5.17%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	102.40%	Profit Margin	-	Rel Volume	0.57	Prev Close	24.45
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 11 AMC	Payout	-	Avg Volume	1.04M	Price	25.18
Recom	1.70	SMA20	-7.50%	SMA50	-11.67%	SMA200	-22.01%	Volume	585,894	Change	2.99%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-31-23	Initiated	Mizuho	Buy	$52
Jan-05-23	Initiated	BofA Securities	Buy	$50
May-25-22	Initiated	Citigroup	Buy	$21
Apr-01-22	Downgrade	Goldman	Buy → Neutral	$36 → $10

May-30-23 08:14AM	Amylyx says European regulator 'trending toward' negative opinion on ALS drug (Reuters)
08:00AM	Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union (Business Wire)
May-16-23 11:29AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2023 Earnings Call Transcript (Insider Monkey)
06:06AM	New Forecasts: Here's What Analysts Think The Future Holds For Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) (Simply Wall St.)
May-14-23 04:00PM	2 Supercharged Growth Stocks to Buy Right Now (Motley Fool)
08:06AM	Loading…
08:06AM	Amylyx Pharmaceuticals, Inc. Just Reported A Surprise Profit, And Analysts Lifted Their Estimates (Simply Wall St.)
May-12-23 04:18PM	These Stocks Are Moving the Most Today: Tesla, First Solar, News Corp, Icahn Enterprises, Twilio, and More (Barrons.com)
04:07PM	Amylyx Unexpectedly Hits Breakeven With Breakneck Speed But Shares Dip (Investor's Business Daily)
08:16AM	Q1 2023 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 05:25PM	Amylyx Pharmaceuticals, Inc. (AMLX) Q1 Earnings and Revenues Surpass Estimates (Zacks)
04:42PM	Amylyx Blows Past Sales Expectations, Reports Unexpected Profit Shares Rocket (Investor's Business Daily)
04:01PM	Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results (Business Wire)
May-05-23 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-20-23 09:00AM	Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America (Business Wire)
Apr-17-23 02:24PM	Loss-Making Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Set To Breakeven (Simply Wall St.)
01:50PM	Loading…
Apr-14-23 01:50PM	Amylyx (AMLX) Doses First Patient in Wolfram Syndrome Study (Zacks)
Apr-13-23 09:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
Apr-11-23 09:00AM	Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-09-23 01:19PM	7 Biotech Stocks to Buy for 100% Returns (InvestorPlace)
Apr-07-23 06:40PM	Tillys, American Public Education Stock See Action From Activist Investors (Barrons.com)
Apr-03-23 06:48AM	Daily Vickers Top Buyers & Sellers for 04/03/2023 (Argus Research)
Mar-30-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/30/2023 (Argus Research) -5.07%
Mar-24-23 06:42AM	Daily Vickers Top Buyers & Sellers for 03/24/2023 (Argus Research)
Mar-18-23 08:11AM	Party Time: Brokers Just Made Major Increases To Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Earnings Forecasts (Simply Wall St.)
Mar-17-23 06:47AM	Daily Vickers Top Buyers & Sellers for 03/17/2023 (Argus Research) -5.58%
Mar-15-23 07:07AM	Amylyx Pharmaceuticals (NASDAQ:AMLX) shareholders are still up 49% over 1 year despite pulling back 5.5% in the past week (Simply Wall St.)
Mar-14-23 04:02PM	Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS Treatment (Investor's Business Daily) +9.40%
12:31PM	Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today (Motley Fool)
11:19AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2022 Earnings Call Transcript (Insider Monkey)
06:30AM	Q4 2022 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
04:03PM	Loading…
Mar-13-23 04:03PM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Mar-08-23 09:00AM	Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Mar-07-23 07:00AM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023 (Business Wire)
Feb-27-23 06:50AM	Daily Vickers Top Buyers & Sellers for 02/27/2023 (Argus Research)
Feb-07-23 09:00AM	Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference (Business Wire)
Feb-02-23 09:00AM	Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS (Business Wire) -6.07%
Jan-17-23 02:00AM	Amylyx Pharmaceuticals Announces Exclusive AMX0035 Distribution Agreement with Israel-Based Neopharm (Business Wire)
Nov-30-22 09:11AM	We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate (Simply Wall St.)
Nov-22-22 09:00AM	Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference (Business Wire) +6.79%
Nov-16-22 11:00AM	Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm (Investor's Business Daily)
Nov-10-22 04:01PM	Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results (Business Wire)
11:13AM	Checking on Amylyx Pharmaceuticals Ahead of Earnings (TheStreet.com)
Nov-07-22 10:42AM	Breakeven On The Horizon For Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) (Simply Wall St.)
Nov-03-22 04:05PM	Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022 (Business Wire)
Oct-24-22 10:13AM	10 Best Pharma Stocks To Buy Now (Insider Monkey)
Oct-16-22 09:48AM	Private equity firms are Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) biggest owners and were rewarded after market cap rose by US$170m last week (Simply Wall St.)
Oct-11-22 04:01PM	Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire)
Oct-10-22 04:48PM	Why a $158,000 Drug With Unclear Benefits Hurts Whole Health System (The Wall Street Journal) +5.24%
Oct-06-22 10:30PM	Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (Business Wire) +10.25%
Oct-05-22 03:42PM	Ice Bucket Challenge Beneficiary Throws Cold Water On Investors (TheStreet.com)
Oct-04-22 06:03PM	Top stocks trending after hours: Twitter, Amylyx Pharmaceuticals, AutoZone, AirBNB (Yahoo Finance)
05:03PM	Stocks moving after hours: Twitter, Amylyx Pharmaceuticals, AutoZone, Airbnb (Yahoo Finance Video)
04:23PM	Amylyx Pharmaceuticals Announces Launch of Public Offering (Business Wire)
06:00AM	BCLI: Relvyrio Approval Shows FDA Flexibility for ALS Treatments (Zacks Small Cap Research)
Oct-03-22 05:52AM	Amylyx lobbies Congress for more insurance coverage of ALS clinics (American City Business Journals) +5.68%
Sep-30-22 04:09PM	Highly Rated Amylyx Pharma Skids After Hard-Fought FDA Approval For ALS Drug (Investor's Business Daily) -6.76%
10:09AM	Amylyx (AMLX) Secures the FDA's Approval for ALS Drug (Zacks)
09:27AM	UPDATE 2-Amylyx prices newly approved ALS drug at $158,000 per year (Reuters)
09:15AM	Amylyxs ALS Drug Is Approved by the FDA (The Wall Street Journal)
08:36AM	Amylyx prices ALS drug at $158,000 for the first year (Reuters)
Sep-29-22 07:22PM	Cambridge biotech wins approval for first ALS drug (American City Business Journals)
06:30PM	Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO for the Treatment of ALS (Business Wire)
05:14PM	Amylyxs ALS drug wins FDA approval despite questionable data (MarketWatch)
04:53PM	UPDATE 1-U.S. FDA approves Amylyx ALS drug (Reuters)
Sep-25-22 09:23AM	3 IPO Stocks That You Want to Own (Motley Fool)
Sep-15-22 01:37PM	A US$723m market cap addition is just what Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insiders like to see after purchasing stock worth US$830k (Simply Wall St.)
Sep-14-22 09:00AM	Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries (Business Wire)
Sep-13-22 05:25PM	Halvorsen Curbs Amylyx Stake After ALS Drug Gets Committee's Approval (GuruFocus.com) +5.23%
05:25PM	Andreas Halvorsen Curbs Amylyx Pharmaceuticals Stake After ALS Drug Gets Committee's Approval (GuruFocus.com)
05:54AM	With ALS drug approval likely on the horizon, Amylyx co-founders want to advocate for patients (American City Business Journals)
Sep-12-22 09:07AM	This Stock Has Delivered a Gain of 100% Over the Past 3 Months. Can You Still Buy? (Motley Fool) -5.89%
09:00AM	Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual Compounds (Business Wire)
Sep-11-22 05:41AM	Does a Revolutionary New ALS Drug Make This Biotech Stock a Buy Now? (Motley Fool)
Sep-09-22 02:23PM	Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98 (Investor's Business Daily) +10.54%
12:23PM	Amylyx (AMLX) Up 51% After FDA Committee Endorses ALS Drug (Zacks)
Sep-08-22 02:42PM	Amylyx gains nearly $600M in market cap after FDA committee gives green light (American City Business Journals) +51.01%
11:19AM	Why Amylyx Pharmaceuticals Stock Is on Fire Today (Motley Fool)
10:19AM	After Initial Skepticism FDA's Adcomm Backs Amylyx's Amyotrophic Lateral Sclerosis Hopeful (Benzinga)
10:09AM	Controversial ALS Drug From Amylyx Gets Rare Second FDA Meeting (Bloomberg)
09:59AM	Amylyx ALS drug backed by FDA, malaria vaccine data looks encouraging (Yahoo Finance Video)
09:39AM	Amylyx ALS Drug Wins Backing of FDA Advisory Panel. The Stock Spikes. (Barrons.com)
Sep-07-22 07:45PM	Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS (Business Wire)
06:59PM	Amylyxs ALS Drug Backed by FDA Advisers (The Wall Street Journal)
06:54PM	FDA advisors give thumbs-up to ALS drug with major caveat (American City Business Journals)
06:47PM	UPDATE 2-Amylyx's ALS drug gets U.S. FDA panel's backing in rare turnaround (Reuters)
10:00AM	Amylyx Pharmaceuticals Stock Trading Halted Today (Business Wire)
02:30AM	The FDA Is Giving Amylyx Another Chance on Its ALS Drug. What to Expect. (Barrons.com)
Sep-06-22 03:12PM	FDA Again Highlights Lacking Data From Amylyx's Amyotrophic Lateral Sclerosis Candidate (Benzinga) -5.14%
Sep-02-22 04:12PM	The FDA's Mixed Messages Sent Amylyx Pharmaceuticals Stock Off A Cliff (Investor's Business Daily) -23.19%
12:15PM	Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035 (Business Wire)
Aug-29-22 08:00AM	These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year (Investor's Business Daily)
Aug-11-22 04:01PM	Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-10-22 08:38AM	Is a Surprise Coming for Amylyx Pharmaceuticals (AMLX) This Earnings Season? (Zacks)
Aug-03-22 09:00AM	Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022 (Business Wire)
Jul-29-22 09:00AM	Amylyx Pharmaceuticals Announces ALBRIOZA is Now Available in Canada for the Treatment of ALS (Business Wire)
Jul-18-22 06:00PM	7 Biotech Stocks to Buy for Q3 (InvestorPlace)
09:00AM	Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases (Business Wire)
Jul-06-22 09:00AM	Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases (Business Wire) +5.59%
Jul-05-22 04:12PM	Why IPO Stock Amylyx Pharmaceuticals Is Beginning To Heat Up Again (Investor's Business Daily)
12:46PM	Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today (Motley Fool)

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FRATES JAMES M	Chief Financial Officer	May 16	Option Exercise	6.88	32,500	223,600	88,176	May 18 08:54 PM
FRATES JAMES M	Chief Financial Officer	May 16	Sale	26.94	32,500	875,451	55,676	May 18 08:54 PM
Yeramian Patrick D	Chief Medical Officer	May 15	Option Exercise	5.68	11,965	67,991	220,382	May 17 04:58 PM
Yeramian Patrick D	Chief Medical Officer	May 15	Sale	29.03	11,965	347,358	208,417	May 17 04:58 PM
Yeramian Patrick D	Chief Medical Officer	Apr 17	Option Exercise	0.99	49,579	49,058	257,996	Apr 19 07:45 PM
Yeramian Patrick D	Chief Medical Officer	Apr 17	Sale	30.54	49,579	1,513,942	208,417	Apr 19 07:45 PM
Morningside Venture Investment	10% Owner	Mar 29	Sale	30.45	29,048	884,512	6,997,302	Mar 31 04:05 PM
Morningside Venture Investment	10% Owner	Mar 28	Sale	30.37	100,000	3,037,000	7,026,350	Mar 29 04:05 PM
Morningside Venture Investment	10% Owner	Mar 27	Sale	30.50	60,964	1,859,561	7,126,350	Mar 29 04:05 PM
Morningside Venture Investment	10% Owner	Mar 21	Sale	31.91	63,448	2,024,494	7,187,314	Mar 23 04:05 PM
Firestone Karen	Director	Mar 16	Buy	31.99	1,000	31,990	1,000	Mar 20 08:22 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 16	Sale	31.86	100,000	3,186,336	2,792,617	Mar 20 08:21 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 16	Sale	31.86	100,000	3,186,236	2,792,617	Mar 20 08:31 PM
Yeramian Patrick D	Chief Medical Officer	Mar 16	Sale	31.87	54,627	1,741,200	149,672	Mar 20 08:25 PM
MILNE GEORGE M JR	Director	Mar 16	Sale	31.89	35,000	1,116,072	862,021	Mar 20 08:25 PM
FRATES JAMES M	Chief Financial Officer	Mar 16	Sale	31.89	32,500	1,036,459	1,509	Mar 20 08:18 PM
Morningside Venture Investment	10% Owner	Mar 16	Sale	32.55	9,122	296,921	7,250,762	Mar 17 04:05 PM
Morningside Venture Investment	10% Owner	Mar 15	Sale	33.27	150,000	4,990,997	7,259,884	Mar 16 04:11 PM
Morningside Venture Investment	10% Owner	Mar 14	Sale	34.54	70,714	2,442,462	7,409,884	Mar 16 04:11 PM
Morningside Venture Investment	10% Owner	Mar 02	Sale	33.75	50,000	1,687,500	7,480,598	Mar 06 09:10 AM
Mazzariello Gina	Chief Legal Officer	Feb 24	Sale	34.49	3,586	123,672	37,414	Feb 28 04:42 PM
Morningside Venture Investment	10% Owner	Feb 23	Sale	35.57	50,000	1,778,267	7,580,598	Feb 24 04:13 PM
Morningside Venture Investment	10% Owner	Feb 22	Sale	36.00	50,000	1,799,836	7,630,598	Feb 24 04:13 PM
Morningside Venture Investment	10% Owner	Feb 22	Sale	34.73	50,000	1,736,352	7,530,598	Feb 28 04:06 PM
FRATES JAMES M	Chief Financial Officer	Dec 30	Option Exercise	6.88	5,000	34,400	36,667	Jan 04 09:33 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Sep 09	Sale	30.23	700,000	21,159,753	1,850,940	Sep 09 09:48 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Sep 08	Sale	29.37	700,000	20,559,887	2,075,470	Sep 09 09:48 PM
ALS Invest 1 B.V.	10% Owner	Jul 06	Sale	20.70	60,609	1,254,642	5,895,280	Jul 08 06:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMLX | Amylyx Pharmaceuticals, Inc.

Upgrade your FINVIZ experience